**Malaria, Hepatitis C, and Latent Tuberculosis Infection**

**Long-Acting Technologies Community Advisory Board (LAT CAB)**

**2021–2024 Term**

**Background**

The [LONGEVITY Project](https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/longevity/) aims to develop novel, long-acting therapeutics and preventives for malaria, hepatitis C virus (HCV), and latent tuberculosis infection (LTBI). [Treatment Action Group (TAG)](https://www.treatmentactiongroup.org/) is coordinating the community engagement aspects and developing treatment literacy materials about long-acting therapeutics and preventives. TAG and the [African Community Advisory Board (AfroCAB)](http://www.afrocab.info/) are supporting the creation and coordination of a LAT CAB, and invite applications from strong, research-literate treatment activists and community leaders in high-burden malaria, HCV, and TB countries and from affected communities and networks. The LAT CAB will not work on HIV long-acting injectables, but will learn from the science and lessons in the HIV field to inform work in these other disease areas.

Applicants do not have to be experts in the science but need to bring strong interest in gaining scientific knowledge to become community experts in research and development (R&D) for long-acting therapeutics and preventives; study and trial design review; and other processes that affect access to these new drugs.

**Objectives**

* Form a dedicated CAB comprised of treatment activists and community leaders to review the state of treatment research, contribute to research protocols including those related to product acceptability, and engage in the research and development (R&D) process, including advising on research questions and trial design, for long-acting therapeutics for HCV and preventives for malaria and latent TB infection (LTBI);
* Strengthen research and scientific literacy among treatment activists and community leaders, in partnership with technical experts, to analyze and review materials at learning sessions and workshops;
* Meet with clinical researchers, developers, contract manufacturing organization(s), and project partners about the scientific, cost/pricing, and access plans for high-, middle-, and low-income countries; and
* Prepare community for and advise on the approaches used to introduce LAT, which may include the development of community recommendations on the R&D.

**Membership Requirements for 2021–2024 Term**

* Interest in HCV, malaria, and TB science and gaining research literacy;
* Basic knowledge in at least one disease area: HCV, malaria, and TB;
* Treatment activist or advocacy experience, or connection to community and/or civil society networks;
* Ability to disseminate information, follow through on tasks, and bring local, national, regional and/or global perspectives on issues;
* Confident to communicate in English (LAT CAB working language);
* Capacity to actively participate in bi-/monthly teleconferences and regular communications via email (approximately 4-6 hours per month);
* Availability to participate in in-person meetings when it is safe to do so (costs covered by TAG, when needed);
* Access to internet.

**Expectations**

* The LAT CAB expects members to commit to a tenure from 2021-2024, or the duration of the LONGEVITY Project.
* The LAT CAB would initially meet every two (2) months, until the clinical trials protocols are developed, then would meet every month. If task-based, smaller working groups form, they could decide the frequency to meet to accomplish a task (e.g., prepare a presentation, statement, etc).
* LAT CAB members can expect to commit to an average of 4-6 hours per month (which could include 1-2 hour meetings, plus preparation and review of materials).
* If in-person meetings become possible again, CAB members may be expected to incorporate travel and time to participate.
* CAB members who miss more than two (2) meetings in a calendar year would be asked to reassess their commitment and participation. Whether to recruit a new member or expand the CAB would be decided on by majority rule.

The LAT CAB is looking for representation that is diverse in geographic region, gender, experience, and disease expertise. Individuals from the global South, high-burden countries, all communities affected by malaria, HIV, HCV, and TB, and from key populations, including people who inject or use drugs, are especially encouraged to apply. This includes anyone irrespective of HIV or other health status, religion, gender, sexual orientation or lifestyle.

**Members are not paid for their participation**, but we work with members to ensure their participation is cost-neutral and can offer to cover communications and related costs for participation. LAT CAB members serve as individuals, not in their capacity as members of, or representatives to, any organization or other affiliation. When it becomes safe to travel to in-person CAB meetings, TAG would sponsor and support members to participate.

**Applications are accepted on a rolling basis.**

**Please submit your application via email to Joelle Dountio:** [**jdountio@treatmentactiongroup.org**](mailto:jdountio@treatmentactiongroup.org)

An independent review committee consists of 3-4 reviewers who will review eligible applications.

*\*\*Application reviewers will keep all information confidential. The applications will not be shared outside the independent review team. No information will be shared in any country contexts or in any external communication.*

*Please answer the following application form. Only complete application materials will be reviewed.* ***Only English-language applications will be accepted. Applicants do not have to disclose any sensitive information.***